Regulatory Updates

MHRA Introduces New Device Registration Fee: What Manufacturers Need to Know

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has updated its “DORS Fees Guidance 2.1”, introducing a new annual fee model for device registration.

MedNet EC-REP

Author

MHRA New Device Registration Fee

From One-Time to Annual Fee

  • Until 31 March 2026, MHRA continues to apply the existing £261 one-off registration fee.
  • From 1 April 2026, a recurring annual fee will replace the one-off fee, based on the number of chargeable GMDN® Level 2 categories (or Level 1 if Level 2 is not defined).
  • Fees will apply per category rather than per device, with pro-rata charges for new devices added mid-year.

Fee Calculation and Payment

  • Annual fees are estimated at around £300 per GMDN category.
  • MHRA will base fees on a snapshot of registered categories on 31 March each year.
  • Payment is due within 90 days of invoicing, and non-payment may suspend registration access.

Changes and Exemptions

  • Updating Letters of Designation, organisation name, or address will no longer incur fees.
  • Re-registering devices in previously paid categories will not trigger additional charges.
  • Only registration of new devices in chargeable categories triggers fees.

Preparing for the New System

Manufacturers and UK Responsible Persons should:

  1. Review device portfolios and ensure correct GMDN® category assignments before 30 March 2026.
  2. Verify contact and company information in the MHRA DORS system.
  3. Plan for the annual payment cycle, starting from 1 April 2026, and budget accordingly.

The shift to an annual fee model supports enhanced post-market surveillance, sustainable regulatory oversight, and encourages accurate device registrations.

Source: MHRA

Related Articles

Intended Purpose vs Intended Use
Regulatory Updates

Regulatory Affairs Bulletin: Intended Purpose vs Intended Use under MDR & IVDR

European regulations EU 2017/745 (MDR) and EU 2017/746 (IVDR) require precise definitions in technical documentation, and the distinction (or overlap) between intended purpose and intended use remains a topic of operational significance. This bulletin clarifies the regulatory definitions, their implications, and guidance interpretations.

MedNet EC-REP

Stay Updated

Get the latest regulatory updates and industry insights delivered to your inbox.

Subscribe to Updates